Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07333053
NA

Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

Sponsor: Quanda Liu

View on ClinicalTrials.gov

Summary

This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).

Official title: FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: An Open-Label, Multicenter, Randomized, Controlled, Phase Ⅱ Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-03-31

Completion Date

2027-12-31

Last Updated

2026-03-06

Healthy Volunteers

No

Interventions

PROCEDURE

Transarterial infusion chemotherapy (TAIC)

TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.

PROCEDURE

Intravenous Chemotherapy(IVC)

Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.

Locations (1)

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Xicheng, Beijing Municipality, China